ZYXI vs ENVA vs WRLD vs STIM

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus -1. 5% for World Acceptance Corporation (WRLD). Zynex, Inc. (ZYXI) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate Enova International, Inc. (ENVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zynex, Inc.

(ZYXI) is the cheapest at 0. 6x versus Enova International, Inc. at 15. 1x. On forward P/E, Enova International, Inc. is actually cheaper at 10. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Enova International, Inc.

(ENVA) delivered a total return of +374. 2%, compared to -98. 9% for Zynex, Inc. (ZYXI). Over 10 years, the gap is even starker: ENVA returned +20. 6% versus STIM's -94. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), World Acceptance Corporation (WRLD) is the lower-risk stock at 1.

31β versus Zynex, Inc. 's 4. 40β — meaning ZYXI is approximately 236% more volatile than WRLD relative to the S&P 500. On balance sheet safety, World Acceptance Corporation (WRLD) carries a lower debt/equity ratio of 120% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus -1. 5% for World Acceptance Corporation (WRLD). On earnings-per-share growth, the picture is similar: Neuronetics, Inc. grew EPS 57. 2% year-over-year, compared to -66. 7% for Zynex, Inc.. Over a 3-year CAGR, STIM leads at 31. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

World Acceptance Corporation (WRLD) is the more profitable company, earning 15.

9% net margin versus -26. 1% for Neuronetics, Inc. — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WRLD leads at 28. 1% versus -21. 1% for STIM. At the gross margin level — before operating expenses — ZYXI leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Enova International, Inc.

(ENVA) trades at 10. 6x forward P/E versus 21. 2x for World Acceptance Corporation — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STIM: 383. 4% to $8. 00.

In this comparison, ZYXI (0.

5% yield) pays a dividend. ENVA, WRLD, STIM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, World Acceptance Corporation (WRLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+266.

6% 10Y return). Neuronetics, Inc. (STIM) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WRLD: +266. 6%, STIM: -94. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYXI (Healthcare) and ENVA (Financial Services) and WRLD (Financial Services) and STIM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYXI is a small-cap deep-value stock; ENVA is a small-cap high-growth stock; WRLD is a small-cap deep-value stock; STIM is a small-cap high-growth stock. ZYXI pays a dividend while ENVA, WRLD, STIM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.